Thursday, January 1, 2015

2014 Portfolio Review

Happy 2015! Time is passing fast, it is time for annual review. :)

Portfolio Summary
Cost is based on market open price on 1 Jan 2013 except My Malaysia Portfolio.
Gain/(Loss) calculation with dividends included.

From the table above, it is clear that return of all portfolio items are decent compare to last year except My HK Portfolio. My US Portfolio is beating both Dow Jone 15 and Fortune 10, +21.57% and +9.45% respectively. My HK Portfolio is lossing both Hang Seng HK 15 and Hang Seng Mainland 12, -14.39% and -3.65% respectively. My Malaysia Portfolio is beating FBMKLCI, +33.2%. In conclusion, my last year investment performance achieved decent return, 2014 is definitely a good year to me :). Please see tables below for detail of each index fund.

US Market
Dow Jones 15

Fortune 10

Hong Kong Market
Hang Seng HK 15

Hang Seng Mainland 12

The Magic Formula Portfolio 2014Q4 Review

In 2014Q2, I started building up The Magic Formula Portfolio following the buy and sell criteria listed in the blog post titled Start Building Up The Magic Formula Portfolio.

As stated in the above blog post, I will review the performance of the portfolio quarterly. The following is the result of 2014Q4, loss 1.79% on 31 Dec 2014.

I sold the following stocks on 31 Dec 2014 as they are no longer exists in the Magic Formula list. 

Total available investment capital is $2,689.65 ($1,795.47 from the balance of investment capital, $20.49 from total dividend received from EBIX and PETS in 2014, and $873.69 from proceeds of sold stocks).  On the 2 Jan 2015, I will add the following stocks except NHTC (as it is an OTC/unlisted stock) to the portfolio:

At this point, it is considered the completion of the build up of the Magic Formula portfolio.

Stay tune to the next quarter! :)

Note (edited on 3 Jan 2015):
6 stocks above added to the portfolio successfully.
 

Disclaimer

The author writing this blog is for personal records and information sharing purpose only, it is not professional investment advices. The author specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. Neither the author shall be liable for any loss of profit or any commercial damages, including but not limited to special, incidental, consequential, or other damages.